AI
BLRX

Atria Investments’s BioLineRX BLRX Stock Holding History

Atria Investments’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,349
Closed -$71.8K – 1863
2024
Q3 		$71.8K Buy
3,349
+729
+28% +$20K ﹤0.01% 1882
2024
Q2 		$59.7K Buy
+2,620
New +$70.3K ﹤0.01% 1888

Other funds holding BLRX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Atria Investments's BLRX Position: Q4 2024 in Review

Atria Investments sold out of BioLineRX (BLRX) in Q4 2024, closing a stake of 3,349 shares — an estimated $71.8K sold.

Atria Investments first reported a position in BLRX in Q2 2024 and held it in 2 quarters. The position peaked at $71.8K in Q3 2024. 31 funds tracked by Wall St. Rank hold BLRX as of Q4 2024.

  • Atria Investments reported no remaining BioLineRX position as of Q4 2024 after selling out during the quarter.
  • Atria Investments sold 3,349 BioLineRX shares in Q4 2024, an estimated $71.8K.
  • Atria Investments first reported a position in BioLineRX in Q2 2024 and held it in 2 quarters.
  • Atria Investments's BioLineRX position peaked at $71.8K in Q3 2024.
  • 31 funds tracked by Wall St. Rank held BioLineRX as of Q4 2024.

Based on Atria Investments's 13F filing for Q4 2024, filed 6 Feb 2025.